Literature DB >> 17919486

Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.

Roopali Bansal Gupta1, Noam Harpaz, Steven Itzkowitz, Sabera Hossain, Sierra Matula, Asher Kornbluth, Carol Bodian, Thomas Ullman.   

Abstract

BACKGROUND & AIMS: Although inflammation is presumed to contribute to colonic neoplasia in ulcerative colitis (UC), few studies have directly examined this relationship. Our aim was to determine whether severity of microscopic inflammation over time is an independent risk factor for neoplastic progression in UC.
METHODS: A cohort of patients with UC undergoing regular endoscopic surveillance for dysplasia was studied. Degree of inflammation at each biopsy site had been graded as part of routine clinical care using a highly reproducible histologic activity index. Progression to neoplasia was analyzed in proportional hazards models with inflammation summarized in 3 different ways and each included as a time-changing covariate: (1) mean inflammatory score (IS-mean), (2) binary inflammatory score (IS-bin), and (3) maximum inflammatory score (IS-max). Potential confounders were analyzed in univariate testing and, when significant, in a multivariable model.
RESULTS: Of 418 patients who met inclusion criteria, 15 progressed to advanced neoplasia (high-grade dysplasia or colorectal cancer), and 65 progressed to any neoplasia (low-grade dysplasia, high-grade dysplasia, or colorectal cancer). Univariate analysis demonstrated significant relationships between histologic inflammation over time and progression to advanced neoplasia (hazard ration (HR), 3.0; 95% CI: 1.4-6.3 for IS-mean; HR, 3.4; 95% CI: 1.1-10.4 for IS-bin; and HR, 2.2; 95% CI: 1.2-4.2 for IS-max). This association was maintained in multivariable proportional hazards analysis.
CONCLUSIONS: The severity of microscopic inflammation over time is an independent risk factor for developing advanced colorectal neoplasia among patients with long-standing UC.

Entities:  

Mesh:

Year:  2007        PMID: 17919486      PMCID: PMC2175077          DOI: 10.1053/j.gastro.2007.08.001

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  28 in total

1.  How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance.

Authors:  J A Eaden; B A Ward; J F Mayberry
Journal:  Gastrointest Endosc       Date:  2000-02       Impact factor: 9.427

2.  Colorectal cancer prevention in ulcerative colitis: a case-control study.

Authors:  J Eaden; K Abrams; A Ekbom; E Jackson; J Mayberry
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

Review 3.  Assessing disease activity and disease activity indices for inflammatory bowel disease.

Authors:  Feng Xiao Li; Lloyd R Sutherland
Journal:  Curr Gastroenterol Rep       Date:  2002-12

4.  Patients with low-grade dysplasia should be advised to undergo colectomy.

Authors:  Thomas A Ullman
Journal:  Inflamm Bowel Dis       Date:  2003-07       Impact factor: 5.325

5.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

6.  Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis.

Authors:  J Eaden; K Abrams; H McKay; H Denley; J Mayberry
Journal:  J Pathol       Date:  2001-06       Impact factor: 7.996

7.  Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.

Authors:  M Engelsgjerd; F A Farraye; R D Odze
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

8.  Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps.

Authors:  P H Rubin; S Friedman; N Harpaz; E Goldstein; J Weiser; J Schiller; J D Waye; D H Present
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

9.  The fate of low grade dysplasia in ulcerative colitis.

Authors:  Thomas A Ullman; Edward V Loftus; Sanjay Kakar; Lawrence J Burgart; William J Sandborn; William J Tremaine
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

10.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.

Authors:  K Geboes; R Riddell; A Ost; B Jensfelt; T Persson; R Löfberg
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

View more
  209 in total

1.  Survival in elderly patients with ulcerative colitis and colorectal cancer.

Authors:  Wojciech Blonski; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

2.  Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study.

Authors:  Wei Gong; Nonghua Lv; Bangmao Wang; Ye Chen; Yinglong Huang; Wenshen Pan; Bo Jiang
Journal:  Dig Dis Sci       Date:  2011-09-22       Impact factor: 3.199

3.  Endoscopy in inflammatory bowel disease when and why.

Authors:  Rajaratnam Rameshshanker; Naila Arebi
Journal:  World J Gastrointest Endosc       Date:  2012-06-16

Review 4.  Mucosal healing in inflammatory bowel disease: where do we stand?

Authors:  Christina Ha; Asher Kornbluth
Journal:  Curr Gastroenterol Rep       Date:  2010-12

5.  Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers.

Authors:  Alexandru V Olaru; Yulan Cheng; Rachana Agarwal; Jian Yang; Stefan David; John M Abraham; Wayne Yu; John H Kwon; Mark Lazarev; Steven R Brant; Michael R Marohn; David F Hutcheon; Noam Harpaz; Stephen J Meltzer; Yuriko Mori
Journal:  Inflamm Bowel Dis       Date:  2011-08-09       Impact factor: 5.325

Review 6.  Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.

Authors:  Britt Christensen; David T Rubin
Journal:  Curr Gastroenterol Rep       Date:  2016-01

7.  Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.

Authors:  Wanying Zhang; Haonan Li; Hua Dong; Jie Liao; Bruce D Hammock; Guang-Yu Yang
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

8.  Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.

Authors:  Joel Pekow; Urszula Dougherty; Yong Huang; Edward Gometz; Jeff Nathanson; Greg Cohen; Shawn Levy; Masha Kocherginsky; Nanda Venu; Maria Westerhoff; John Hart; Amy E Noffsinger; Stephen B Hanauer; Roger D Hurst; Alessandro Fichera; Loren J Joseph; Qiang Liu; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

9.  Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis.

Authors:  D H Johnson; S Khanna; T C Smyrk; E V Loftus; K S Anderson; D W Mahoney; D A Ahlquist; J B Kisiel
Journal:  Aliment Pharmacol Ther       Date:  2014-04-30       Impact factor: 8.171

10.  Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis.

Authors:  Burton I Korelitz; Keith Sultan; Megha Kothari; Leo Arapos; Judy Schneider; Georgia Panagopoulos
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.